[Administration-limiting factor of bevacizumab for patient with metastatic colorectal cancer].
Division of Medical Oncology Center, Cancer Institute Hospital of Japanese Foundation for Cancer Research.
Yoshimasa
Y
Kawazoe
Kiyohiko
K
Hatake
Mitsukuni
M
Suenaga
Nobuyuki
N
Mizunuma
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000068258:Bevacizumab; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D006801:Humans; D009362:Neoplasm Metastasis
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab